ReviewJournal of the American Society of Nephrology : JASN2018
Targeting B Cells and Plasma Cells in Glomerular Diseases: Translational Perspectives.
Review in Journal of the American Society of Nephrology : JASN, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06711354 (B-cell Depletion in Offspring to Women With MS and Rituximab Treatment Before or During Pregnancy), which is not on this map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
B-cell Depletion in Offspring to Women With MS and Rituximab Treatment Before or During Pregnancy
Who cites it
37 citing papers in PubMed, 60 citations in OpenAlex.
- A multicenter, randomized, open-label, phase 2 clinical study of telitacicept in adult patients with generalized myasthenia gravis.European journal of neurology · 2024Trial
- Marginal-Zone B-Cells Are Main Producers of IgM in Humans, and Are Reduced in Patients With Autoimmune Vasculitis.Frontiers in immunology · 2018Trial
- Single-dose rituximab as induction therapy in adult IgA vasculitis with rapidly progressive glomerulonephritis: a case report with peripheral blood CD19⁺ B-cell monitoring.CEN case reports · 2026Article
- Effect of Steroids on Anti-nephrin Autoantibodies and B cells in Minimal Change Disease.Kidney international reports · 2026Article
- Review
- Low-dose rituximab for MPO-ANCA-associated hypertrophic pachymeningitis with delayed onset of renal involvement: a case report.Frontiers in medicine · 2026Article
- CAR-T cell therapy in nephrology.Renal failure · 2025Review
- Prolonging calcineurin inhibitor therapy post kidney allograft failure: a prospective study.Renal failure · 2025Article
- Comparison of B lymphocyte profile between membranous nephropathy and idiopathic nephrotic syndrome pediatric patients.Pediatric nephrology (Berlin, Germany) · 2025Article
- Exploration of rituximab treatment strategies for membranous nephropathy adapted to the Chinese healthcare environment.BMC nephrology · 2025Article
- Telitacicept as double-targeted therapy for myasthenia gravis coexisting with connective tissue disease: three case reports.Frontiers in immunology · 2025Article
- Revolutionizing Autoimmune Kidney Disease Treatment with Chimeric Antigen Receptor-T Cell Therapy.Research (Washington, D.C.) · 2025Review
- What is new in the pathogenesis and treatment of IgA glomerulonephritis.World journal of nephrology · 2024Review
- New Insights and Future Perspectives of APRIL in IgA Nephropathy.International journal of molecular sciences · 2024Review
- An Update on Current Therapeutic Options in IgA Nephropathy.Journal of clinical medicine · 2024Review
- A PRoliferation-Inducing Ligand (APRIL) in the Pathogenesis of Immunoglobulin A Nephropathy: A Review of the Evidence.Journal of clinical medicine · 2023Review
- Immune podocytes in the immune microenvironment of lupus nephritis (Review).Molecular medicine reports · 2023Review
- The place of cyclical therapy for the treatment of membranous nephropathy in the era of rituximab.Clinical kidney journal · 2023Article
- Combination of Rituximab and Low-dose Tacrolimus in the Treatment of Refractory Membranous Nephropathy: A Retrospective Cohort StudyBalkan medical journal · 2023Article
- Leukocyturia and hematuria enable non-invasive differentiation of Bowman's capsule rupture severity in PR3-ANCA glomerulonephritis.Journal of nephrology · 2023Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The unique contributions of memory B cells and plasma cells in kidney diseases remain unclear. In this review, we evaluate the clinical experience with treatments directed at B cells, such as rituximab, and at plasma cells, such as proteasome inhibition, to shed light on the role of these two B lineage compartments in glomerular diseases. Specifically, analysis of these targeted interventions in diseases such as ANCA-associated vasculitis, SLE, and antibody-mediated transplant rejection permits insight into the pathogenetic effect of these cells. Notwithstanding the limitations of preclinical models and clinical studies (heterogeneous populations, among others), the data suggest that memory B and plasma cells represent two engines of autoimmunity, with variable involvement in these diseases. Whereas memory B cells and plasma cells appear to be key in ANCA-associated vasculitis and antibody-mediated transplant rejection, respectively, SLE seems likely to be driven by both autoimmune compartments. These conclusions have implications for the future development of targeted therapeutics in immune-mediated renal disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.